创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology:3D Organoid Platform Features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-07 14:20
  • Views:

(Summary description)In the field of biomedicine, we have been searching for a technology that can better mimic the structure and physiological functions of complex organs in the human body. This quest has been dramatically demonstrated in the 3D organoid platform from InnoModels Biotechnology. With its unique advantages, this platform is gradually leading a new trend in biomedical research.

InnoModels Biotechnology:3D Organoid Platform Features

(Summary description)In the field of biomedicine, we have been searching for a technology that can better mimic the structure and physiological functions of complex organs in the human body. This quest has been dramatically demonstrated in the 3D organoid platform from InnoModels Biotechnology. With its unique advantages, this platform is gradually leading a new trend in biomedical research.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-07 14:20
  • Views:
Information

In the field of biomedicine, we have been searching for a technology that can better mimic the structure and physiological functions of complex organs in the human body. This quest has been dramatically demonstrated in the 3D organoid platform from InnoModels Biotechnology. With its unique advantages, this platform is gradually leading a new trend in biomedical research.
1. Multi-cell type support: simulating complex organ structures
The 3D organoid platform of InnoModels Biotechnology supports the self-assembly of multiple cell types, which can simulate complex organ structures, such as liver, heart, lungs, etc. This feature allows researchers to simulate complex organ structures in vivo. This feature allows researchers to more realistically simulate the physiological and pathological processes of organs in the human body in an in vitro environment, thus providing an experimental platform closer to the actual biological environment for disease research and drug development.

 


2、Physiological function restoration: closer to the biological characteristics of internal organs
Through carefully designed culture conditions and support structures, the 3D organoid platform can better restore the physiological functions of organoids. This high degree of physiological reproducibility makes the results of in vitro experiments more informative and provides more accurate guidance for drug development and disease treatment.
3、High-throughput screening: accelerating the drug development and evaluation process
In addition to providing a highly restorative biological environment, the 3D organoid platform of InnoModels Biotechnology also supports high-throughput experiments. This feature greatly accelerates the drug screening and evaluation process, thus shortening the drug development cycle and bringing earlier treatment opportunities to patients with diseases.
In conclusion, the 3D organoid platform of InnoModels Biotechnology opens up a new path for biomedical research with its unique features of multi-cell type support, physiological function reduction and high-throughput screening. The emergence of this platform not only improves the accuracy and reliability of in vitro experiments, but also accelerates the process of drug development and evaluation, bringing new hope for disease treatment. With the continuous development and improvement of the technology, we have reason to believe that the 3D organoid platform of InnoModels will bring more surprises and breakthroughs to the biomedical field in the future.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司